Sahpra’s take on GLP-1 medication use for weight loss in SA.
Loading player...
GUEST: Mokgadi Fafudi – Head of Regulatory Compliance, SAHPRA
As South Africa joins the global weight-loss medication boom, Aspen Pharmacare has just secured approval to market Eli Lilly’s blockbuster drug Mounjaro for chronic weight management. But with growing demand comes growing risk from counterfeit products to off-label use and online scams.
SAHPRA’s Mokgadi Fafudi unpacks what GLP-1 drugs like Ozempic and Mounjaro actually are, how the regulator is responding to the surge in unregistered or fake versions, and what the new approval means for South Africans seeking safe, legitimate weight-loss treatments.
As South Africa joins the global weight-loss medication boom, Aspen Pharmacare has just secured approval to market Eli Lilly’s blockbuster drug Mounjaro for chronic weight management. But with growing demand comes growing risk from counterfeit products to off-label use and online scams.
SAHPRA’s Mokgadi Fafudi unpacks what GLP-1 drugs like Ozempic and Mounjaro actually are, how the regulator is responding to the surge in unregistered or fake versions, and what the new approval means for South Africans seeking safe, legitimate weight-loss treatments.
